ZA968956B - Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients - Google Patents

Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients

Info

Publication number
ZA968956B
ZA968956B ZA968956A ZA968956A ZA968956B ZA 968956 B ZA968956 B ZA 968956B ZA 968956 A ZA968956 A ZA 968956A ZA 968956 A ZA968956 A ZA 968956A ZA 968956 B ZA968956 B ZA 968956B
Authority
ZA
South Africa
Prior art keywords
substituted
active ingredients
pharmaceutical active
imidazolidinedione compounds
imidazolidinedione
Prior art date
Application number
ZA968956A
Other languages
English (en)
Inventor
Oswald Zimmer
Horst Boehlke
Stephan Wnendt
Cornelia Geist
Kai Zwingenberger
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of ZA968956B publication Critical patent/ZA968956B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA968956A 1995-10-27 1996-10-24 Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients ZA968956B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19540027A DE19540027A1 (de) 1995-10-27 1995-10-27 Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe

Publications (1)

Publication Number Publication Date
ZA968956B true ZA968956B (en) 1997-05-29

Family

ID=7775931

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA968956A ZA968956B (en) 1995-10-27 1996-10-24 Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients

Country Status (23)

Country Link
US (1) US6004963A (fr)
EP (1) EP0770613B1 (fr)
JP (1) JPH09188677A (fr)
KR (1) KR100445539B1 (fr)
CN (1) CN1097050C (fr)
AR (1) AR004517A1 (fr)
AT (1) ATE181072T1 (fr)
AU (1) AU707751B2 (fr)
CA (1) CA2188908A1 (fr)
CO (1) CO4750655A1 (fr)
DE (2) DE19540027A1 (fr)
DK (1) DK0770613T3 (fr)
ES (1) ES2135148T3 (fr)
GR (1) GR3030558T3 (fr)
HK (1) HK1010367A1 (fr)
HU (1) HU222120B1 (fr)
IL (1) IL119488A (fr)
MX (1) MX9605023A (fr)
PE (1) PE20011055A1 (fr)
PL (1) PL184446B1 (fr)
RU (1) RU2163603C2 (fr)
SI (1) SI0770613T1 (fr)
ZA (1) ZA968956B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
DE19917961A1 (de) 1999-04-21 2000-10-26 Degussa Verfahren zur Herstellung von Aminosäurederivaten
US6350763B1 (en) * 1999-07-21 2002-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammation disease
EP1284973B1 (fr) * 2000-05-31 2007-06-27 Tanabe Seiyaku Co., Ltd. Inhibiteurs des adhesions cellulaires induites par integrine alpha l beta 2
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2005090316A1 (fr) * 2004-03-12 2005-09-29 Wyeth Hydantoines a activite modulatrice de la rnase
EP1621536A1 (fr) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Dérivés d'urées cycliques aminés, leur préparation et utilisation pharmaceutique en tant qu'inhibiteurs de Kinase
EP1621535A1 (fr) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Dérivés substitués d'urée cyclique, leur préparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1621539A1 (fr) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Dérivées d'urée cyclique substitués par un heterocycle, leur prépration et leur utilisation pharmaceutique comee inhibiteurs de kinases
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
SI2368550T1 (sl) * 2006-03-27 2013-11-29 The Regents Of The University Of California Modulator androgenskih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenskimi receptorji
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008021337A1 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés oxazinan-2-one utiles comme modulateurs pr
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US7652018B2 (en) * 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
EP2069335B1 (fr) * 2006-09-08 2012-12-26 Actelion Pharmaceuticals Ltd. Dérivés de pyridin-3-yle en tant qu'agents immunomodulateurs
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
KR20110022089A (ko) * 2008-06-27 2011-03-04 노파르티스 아게 유기 화합물
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
DK3124481T3 (en) 2010-02-16 2018-05-07 Aragon Pharmaceuticals Inc ANDROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091596B1 (fr) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Hydantoins, préparation et application
US4746669A (en) * 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants
JPH02101065A (ja) * 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
CA2095429A1 (fr) * 1990-11-06 1992-05-07 Paul E. Bender Composes d'imodazolidinone
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US7466669B2 (en) * 2003-11-14 2008-12-16 Telefonaktiebolaget Lm Ericsson (Publ) Reverse link scheduler for CDMA networks

Also Published As

Publication number Publication date
US6004963A (en) 1999-12-21
ATE181072T1 (de) 1999-06-15
SI0770613T1 (en) 1999-10-31
DE19540027A1 (de) 1997-04-30
AR004517A1 (es) 1998-12-16
PE20011055A1 (es) 2001-12-29
CA2188908A1 (fr) 1997-04-28
HU9602932D0 (en) 1996-12-30
KR100445539B1 (ko) 2004-12-30
MX9605023A (es) 1997-06-28
IL119488A (en) 2001-01-11
EP0770613A1 (fr) 1997-05-02
AU6818196A (en) 1997-05-01
PL316706A1 (en) 1997-04-28
RU2163603C2 (ru) 2001-02-27
DK0770613T3 (da) 1999-12-13
HUP9602932A3 (en) 1998-08-28
CO4750655A1 (es) 1999-03-31
PL184446B1 (pl) 2002-10-31
CN1152573A (zh) 1997-06-25
DE59602155D1 (de) 1999-07-15
IL119488A0 (en) 1997-01-10
JPH09188677A (ja) 1997-07-22
ES2135148T3 (es) 1999-10-16
EP0770613B1 (fr) 1999-06-09
CN1097050C (zh) 2002-12-25
AU707751B2 (en) 1999-07-22
HUP9602932A2 (hu) 1998-07-28
HK1010367A1 (en) 1999-06-17
KR970021076A (ko) 1997-05-28
HU222120B1 (hu) 2003-04-28
GR3030558T3 (en) 1999-10-29

Similar Documents

Publication Publication Date Title
ZA968956B (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
ZA965866B (en) 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
HK1001860A1 (en) I-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
PL323152A1 (en) Derivatives of 1,3-propanodiole as biologically active compounds
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
HUP9802822A3 (en) Halobenzimidazol derivatives, intermediates, preparation thereof and microbocide compositions containing these compounds as active ingredients
EP0727217A3 (fr) Compositions pharmaceutiques et cosmétiques contenant ellagitannin du type god comme principe actif
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
IL190215A0 (en) Novel substituted imidazole compounds, their preparation and pharmaceutical compositions comprising them
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
HUP9802304A3 (en) Pyridazin-3-one derivatives, intermediates, use thereof, insecticide compositions containing these compounds as active ingredients
ZA972147B (en) Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients.
IL118426A0 (en) Pharmaceutical composition containing 1,3-bis-triazolyl-2- propanol derivative
IL116746A0 (en) Use of 3, 4-diphenyl chromans for the preparation of pharmaceutical compositions
NZ318391A (en) Fungicidal compositions comprising fenazaquine as an active substance
ZA961138B (en) Solid active ingredient compositions containing hydroxypropylcellulose.
HUP9900365A3 (en) N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
IL117943A0 (en) Dihalopropene compounds, insecticides containing them as active ingredients and intermediates for their production
HUP9801133A3 (en) 1,2,4-triazole-derivatives, fungicide compositions containing these compounds as active ingredients
ZA966916B (en) Insecticidally active composition.
IL116828A0 (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions
IL116745A0 (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions
HK1017667A1 (en) Pesticide compounds, compositions and process for the preparation thereof
IL116826A0 (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions
HUP0002958A3 (en) Fungicidal 4-cyano-4-deformyl-sordaricin derivatives, pharmaceutical and agricultural compositions containing the same